CA3242160A1 - Multifuntional molecules binding to tcr and uses thereof - Google Patents

Multifuntional molecules binding to tcr and uses thereof

Info

Publication number
CA3242160A1
CA3242160A1 CA3242160A CA3242160A CA3242160A1 CA 3242160 A1 CA3242160 A1 CA 3242160A1 CA 3242160 A CA3242160 A CA 3242160A CA 3242160 A CA3242160 A CA 3242160A CA 3242160 A1 CA3242160 A1 CA 3242160A1
Authority
CA
Canada
Prior art keywords
multifuntional
tcr
molecules binding
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242160A
Other languages
English (en)
French (fr)
Inventor
Madan Katragadda
Jonathan Hsu
Andrew BAYLIFFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marengo Therapeutics Inc
Original Assignee
Marengo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marengo Therapeutics Inc filed Critical Marengo Therapeutics Inc
Publication of CA3242160A1 publication Critical patent/CA3242160A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
CA3242160A 2021-12-22 2022-12-21 Multifuntional molecules binding to tcr and uses thereof Pending CA3242160A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163292859P 2021-12-22 2021-12-22
US63/292,859 2021-12-22
PCT/US2022/053705 WO2023122206A2 (en) 2021-12-22 2022-12-21 Multifuntional molecules binding to tcr and uses thereof

Publications (1)

Publication Number Publication Date
CA3242160A1 true CA3242160A1 (en) 2023-06-29

Family

ID=86903607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242160A Pending CA3242160A1 (en) 2021-12-22 2022-12-21 Multifuntional molecules binding to tcr and uses thereof

Country Status (9)

Country Link
US (1) US20240409636A1 (https=)
EP (1) EP4453039A4 (https=)
JP (1) JP2025500522A (https=)
KR (1) KR20240161975A (https=)
CN (1) CN118786150A (https=)
AU (1) AU2022419371A1 (https=)
CA (1) CA3242160A1 (https=)
GB (1) GB2631849A (https=)
WO (1) WO2023122206A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
AU2024264260A1 (en) * 2023-04-27 2025-11-13 Marengo Therapeutics, Inc. Combination therapies using molecules binding to tcr
WO2025049771A1 (en) * 2023-08-30 2025-03-06 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2025147334A1 (en) * 2024-01-05 2025-07-10 Bright Biologics Llc ANTI-c-MET/HER2 ANTIBODIES AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001227966A1 (en) * 2000-01-20 2001-07-31 Chiron Corporation Methods for treating tumors
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN116234829A (zh) * 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
GB2612450A (en) * 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof

Also Published As

Publication number Publication date
EP4453039A2 (en) 2024-10-30
JP2025500522A (ja) 2025-01-09
WO2023122206A2 (en) 2023-06-29
US20240409636A1 (en) 2024-12-12
WO2023122206A3 (en) 2023-08-31
KR20240161975A (ko) 2024-11-13
GB2631849A (en) 2025-01-15
AU2022419371A1 (en) 2024-07-11
EP4453039A4 (en) 2025-12-17
GB202409147D0 (en) 2024-08-07
CN118786150A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
CA3242160A1 (en) Multifuntional molecules binding to tcr and uses thereof
WO2024254611A3 (en) Multispecific molecules binding to tcr and uses thereof
WO2022216993A3 (en) Multifuntional molecules binding to tcr and uses thereof
AU2020224680B2 (en) Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
NZ793889A (en) Antibody to human interleukin-4 receptor α, preparation method therefor and use thereof
GB0315909D0 (en) Multi-leaf collimator
WO2002099084A3 (en) Composite binding polypeptides
WO2006109191A3 (en) Human anti-interferon gamma antibodies and methods of use thereof
AU2021403658A9 (en) Recombinant cd3 binding proteins and their use
EP1800690A3 (en) Use of fungal immunomodulatory protein
WO2023230626A3 (en) Ph-selective anti-cd3 antibodies and use of the same
EP4165082A4 (en) TNFR2-BINDING ANTIBODIES AND USES THEREOF
CA3261121A1 (en) ANTIBODIES THAT BIND TO HUMAN PAD4 AND THEIR USES
CA3265385A1 (en) DLL3 BINDING MOLECULES AND THEIR USES
WO2023205793A3 (en) Siglec-8 binding proteins and uses thereof
WO2025222063A3 (en) Multifunctional molecules binding to tcr and uses thereof
WO2005036127A3 (en) Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
NZ333456A (en) Type-2 chemokine binding proteins and methods of use therefor
CA2380943A1 (en) Mechanically elongated neuronal cells and methods for producing and using these cells
WO2025217371A3 (en) Multifunctional molecules binding to tcr and uses thereof
DE602005022868D1 (de) Alpha-aminosäurederivate mit entzündungshemmender wirkung
HK40111280A (en) Multifuntional molecules binding to tcr and uses thereof
CA3270551A1 (en) Multifunctional molecules binding to tcr and uses thereof
HK40130621A (en) Multifunctional molecules binding to tcr and uses thereof
IL318770A (en) NKG2D, CD16, and CEACAM5 binding proteins

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241213

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20251128